Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Thought Leadership, Rare diseases
Leveraging Early Access Programs and Real-World Data for commercial success
Blogs/Articles, Rare diseases
Mitigating Risks in Early Access Programs: A Guide for Biotech Companies
Blogs/Articles, Rare diseases
Planning your EU orphan drug stock management with Sciensus
Blogs/Articles, Rare diseases
Packaging and label compliance in Europe: Successfully navigating regulations with Sciensus
News, Rare diseases
Sciensus partners with Sentynl Therapeutics
Thought Leadership, Rare diseases
Launching successful patient support programs for rare disease patients across Europe
Thought Leadership, Rare diseases
Sciensus webinar with Fierce Biotech: Unlocking the European orphan drug market
Blogs/Articles, Rare diseases
Orphan drugs: How to avoid costly stock losses in Europe
Blogs/Articles, Rare diseases
Compassionate use programs in Europe: all you need to know